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1. REPORT SYNOPSIS 
TITLE: A descriptive study to determine the prevalence of 
TPMT polymorphism in Healthy Male Subjects in 
Central South Africa 
PRIMARY RESEARCHER: Dr M.M. Ferreira 
SITE of RESEARCH: PAREXEL Bloemfontein, Early Phase Clinical Unit, South 
Africa 
SPONSOR: N/A 
PROTOCOL NUMBER: N/A 
FINAL PROTOCOL DATE: 09 January 2014 
INTRODUCTION Thiopurine medications e.g. Azathioprine and 6-
Mercaptopurine are metabolized by the thiopurine 
methyltransferase (TPMT) enzyme. This enzyme activity 
is highly variable due to polymorphism of the TPMT gene. 
TPMT genotyping can be performed to tailor the treatment 
with thiopurine medications specifically to the patient's 
TPMT activitv. 
HYPOTHESIS It was expected that the prevalence of TPMT 
polymorphism in Central South Africa will correlate with 
that available in the literature in terms of most prevalent 
polymorphisms, as well as differences in Caucasians, 
Africans and Mixed Race healthy male population. 
RATIONALE Determine the prevalence of TPMT polymorphism in 
and OBJECTIVES: healthy male subjects in Central South Africa. 
STUDY DESIGN: This is a descriptive retrospective study to determine the 
prevalence of TPMT polymorphism in healthy male 
subiects in Central South Africa 
SELECTION CRITERIA: Healthy male subjects who took part in 4 clinical • 
trials performed between 23 February 2009 and 29 
February 2012 at the PAREXEL Bloemfontein 
Early Phase unit were included in the study. 
• Five hundred and forty (540) samples with 
available TPMT blood tests were included in the 
analysis; since some of the studies only tested for 
certain allele mutations, there were missing data 
for some of the analysis. 
STUDY DURATION: Approval was received from the Stellenbosch University 
HREC on 02 December 2013. Study data collection and 
data analysis were performed between 02 December 2013 
and 07 January 2014. TPMT were analysed during 4 
clinical trials performed between 23 February 2009 and 29 
February 2012 at the PAREXEL Bloemfontein Early Phase 
unit. 
ENDPOINTS/ Primary 
MEASUREMENTS: • to determine the prevalence of TPMT 
polymorphisms in healthy male subjects in Central 
South Africa 
• to determine the different alleles that were most 
prevalent in different racial groups in healthy male 
subiects in Central South Africa 
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• to compare the prevalence of mutant alleles in 
healthy male subjects in Central South Africa with 
data from literature. 
INTERVENTION: Not applicable 
SAMPLE SIZE: No formal sample size calculation was performed for this 
study, but 540 samples were available for analysis. 
STATISTICAL ANALYSIS: The statistical evaluation of the study data were performed 
by the Center of Statistical Consultation at the University 
of Stellenbosch and the Division of Biostatistics and 
Programming, PAREXEL Early Phase Bloemfontein. Data 
were analyzed using SAS 9.2 and 9.3. 
RESULTS 
The 95% confidence interval for the binary proportions 
was used to estimate the study population prevalence. If 
small prevalence rates were observed, exact methods 
were used to calculate these confidence limits. 
In comparing the prevalence across different ethnic 
groups, a Chi-squared test was used. When small 
expected frequencies were observed a Fishers exact test 
for 2x2 tables and an exact test for rxc tables were used to 
determine the association. 
To compare the prevalence rates to literature data, the 
assumption was made that the literature data are 
described as a constant; the analysis were a single 
sample T-test for proportions and a Chi-squared test. 
A 5% sianificance level was assumed throuahout. 
Of the total study population, 89.63% tested normal 
(homozygous wild type) for TPMT enzyme activity. The 
remaining study population had polymorphisms for the 
TPMT enzyme activity. Of these approximate 10%, 6.11% 
were intermediate metabolizers and 4.26% were poor 
metabolizers. 
For exon *2 0.89% Black and 2.43% Caucasian subjects 
tested heterozygous. None of the Mixed Race subjects 
tested heterozygous for exon *2. 
For exon *3A 4.81% Caucasians and 4.76% Mixed Race 
subjects tested heterozygous. Caucasians tested 
homozygous mutant in only 1.07% of the total study 
population, but 9.52% of the Mixed Race subjects tested 
homozygous mutant. None of the Black subjects tested 
either heterozygous or homozygous mutant for exon *3A. 
For exon *3B, 5.65% Black, 7.51% Caucasian and 20.00% 
Mixed Race subjects tested heterozygous. Homozygous 
mutant results were only seen in 0.87% Black subjects, 
but not at all in Caucasian and Mixed Race subjects. In 
Caucasian subjects 2.82% tested positive for *3B, but a 
breakdown of the different mutations were not done by the 
annlicable laboratorv, so it can be either heterozvnous or 
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homozygous mutant. 
With exon *3C, 1.59% Black, 1.53% Caucasian and 7.41% 
Mixed Race subjects tested heterozygous. No Black 
subjects tested homozygous mutant, but 3.45% 
Caucasians and 3. 7% Mixed Race subjects tested 
homozygous mutant. There were no Mixed Race subjects 
testing positive for exon *3C, but 1.99% Black and 2.3% 
Caucasian subjects tested positive. Again, no breakdown 
of the different mutations was done by the applicable 
laboratory for this exon. 
None of the subjects tested abnormal for exon *4. 
In comparison to the literature, there is a difference for the 
intermediate and poor metabolizer prevalence. The 
difference is 4.26% for poor metabolizers compared to 
0.3% according to the literature. There were 6.11 % 
intermediate metabolizers in this study, compared to 
approximately 10% according to the literature. 
This difference may be clinically important as poor 
metabolizers can present with severe, even life 
threatening adverse events when treated with thiopurine 
medications. 
The most prevalent mutation in all the races in the study 
population was *3B, which is different from other 
populations in the world. 
It might be possible that Black patients don not have to be 
tested for exon *3A when started on thiopurine 
medications. Also, no patient might need testing for exon 
*4, as none of the 540 subjects tested abnormal for this 
exon. Another interesting finding was that 20% of Mixed 
Race subjects had a heterozygous polymorphism for exon 
*3B and therefore a 5th of this population group may be 
intermediate or poor metabolizers. 
This information can be used to tailor each patient's 
treatment with thiopurine medications. More research is 
needed to determine if routine testing before starting these 
medications is cost-effective or if these tests should only 
be considered when a patient experiences adverse 
effects. 
Although it were expected that the number of poor and 
intermediate metabolizers would be similar to data that are 
available in the literature, it was confirmed that the 
percentage of poor metabolizers were more than reported 
in the literature. The percentage of normal metabolizers 
was similar to literature data. 
The most prevalent mutation in healthy male subjects in 
Central South Africa were *3B, which is different from 
literature of other populations in the world. 
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2. ETHICAL AND LEGAL OBLIGATIONS 
2.1. Good Clinical Practice 
The clinical studies were conducted according to the protocol and to Standard 
Operating Procedures (SOPs) that meet the guidelines laid down by the International 
Conference on Harmonisation (ICH) for Good Clinical Practice (GCP) in clinical trials 
and Guidelines for Good Practice in the Conduct of Clinical Trials in South Africa. 
2.2. Health Research Ethics Committee 
Approval (HREC) 
Written approval of the final version of the study protocol and applicable documents 
were obtained from the HREC of the University of Stellenbosch (HREC number: 
S13/10/185) on 03 December 2013 where after the first collection of data commenced. 
2.3. Regulatory Authority Approval (if 
applicable) 
Not applicable. 
2.4. Subject Confidentiality 
All data were handled in a coded format and all subject personal information remained 
confidential and was documented anonymously. 
All the sponsors, as well as the specific study investigation medicinal products (IMP) of 
the clinical trials performed remained confidential during this research study. 
Page 9 of 24 
Report Number: S13/10/185 Final 1.0, Date: 09 January 2014 
3. LITERATURE REVIEW/ RATIONALE 
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme that catalyses the S-
methylation of thiopurine medications e.g. azathioprine and 6-mercaptopurine. The 
metabolism of 6-mercaptopurine is competitive between TPMT and two other enzymes 
(xanthine and hypoxanthine guanine phosphoribosyltranferase ). TPMT converts 6-
mercaptopurine into an inactive form, 6-methylmercaptopurine, while hypoxanthine 
guanine phosphoribosyltransferase converts 6-mercaptopurine into an active form, 6-
thioguanine (6-TGN)1. TPMT activity correlates inversely with 6-TGN levels in 
erythrocy1es and presumably other hematopoietic tissues, since these cells have 
negligible xanthine oxidase (involved in the other inactivation pathway) activities, 
leaving TPMT methylation as the only inactivation pathway. The cytotoxicity of 
azathioprine is due, in part, to the incorporation of 6-TGN into DNA2. 
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Figure 1: Metabolism pathway of azathioprine: competing pathways result in inactivation by TPMT 
or XO, or incorporation of cytotoxic nucleotides into DNA. 
TPMT activity is highly variable: in a study performed by Lennard et. al. in the 
Children's Hospital, Sheffield, United Kingdom, in acute lymphoblastic leukaemia 
children, 90% of individuals had high/normal activity; approximately 10% have 
intermediate activity and 0.3% low/absent activity. The activity is largely influenced by 
polymorphisms in the TPMT gene3. 
Thiopurines are very useful medications for the treatment of autoimmune disease (e.g. 
Crohn's disease and rheumatoid arthritis), leukaemia, Hodgkin's lymphoma, multiple 
myeloma and after renal transplantation2. They have a relatively narrow therapeutic 
index, with life-threatening myelosuppression as a major toxicity4. There is some 
evidence that suggests that pre-treatment TPMT testing may be effective in reducing 
the number of profound neutropenic episodes experienced by patients prescribed 
azathioprine3. Recording of myelosuppression adverse events indicate that in a 
number of cases the outcome is death5 , therefore it is imperative to have the enzyme 
activity level before starting with treatment. 
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Over 23 variants in the TPMT gene, associated with decreased TPMT activity, have 
been identified. Three variant alleles, TPMT*2, TPMT*3A and TPMT*3C account for 
80 - 95% of intermediate or low activity cases3. 
There are many differences in polymorphism in different races. These differences 
were determined in a number of studies in various areas in the world. 
In a study done by Hon et. al. to investigate the polymorphism in TPMT in American 
Caucasians and African Americans, there was a difference in prevalence of the 3 main 
polymorphisms between the two racial groups. In this study the TPMT*3C allele was 
the most prevalent mutant allele in the African-Americans, whereas the TPMT*3A allele 
was the most prevalent mutant allele in the American Caucasian population6. 
A study was done by Spire-Vayron de la Moureyre et. al. in 191 European individuals. 
Fourteen mutations (of which one was novel) were detected. Four of them were 
mutations characterizing allelic variants TPMT *2, *3A, *3C and *7. Six were mutations 
characterizing different variable number of tandem repeats (VNTR) in the promoter 
region and 4 were silent mutations. Allele *3A was determined to be the most 
detrimental mutation7 . 
In another study done by Bosson et. al. in a heterogeneous Brazilian population, it was 
determined that TPMT *2, *3A and *3C alleles were present at a 2.2%. 1.5% and 1.0% 
frequency respectively". The ethnicity of the population with polymorphism was as 
follows: 
Table 1: f Ethnicity o TPM T alleles in a B l raz1 1an popu at1on 8 
TPMT *2 TPMT *3A TPMT *3B TPMT *3C 
White 3 1 1 4 
Non-white 4 2 3 3 
A study by Hakooz et. al. in the Jordanian population determined that TPMT*3C (0.3%) 
and TPMT*3A (0.89%) were the only mutant alleles found in a sample of 169 
individuals9 . 
4. HYPOTHESIS 
It was expected that the prevalence of TPMT polymorphism will be the same in Central 
South Africa as in the literature in terms of most prevalent polymorphisms as well as 
differences in Caucasians, Africans and Mixed Race healthy male subjects. 
5. RESEARCH AIMS AND OBJECTIVES 
Research Aim: Determine the prevalence of TPMT polymorphism in healthy male 
subjects in Central South Africa. Only male subjects were included in the clinical trials, 
therefore only male subjects were included in this study. 
6. INVESTIGATIONAL PLAN 
6.1. Study design 
This is a descriptive retrospective study to determine the prevalence of TPMT 
polymorphisms in healthy male subjects in Central South Africa. 
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6.2. Objectives (Endpoints) 
6.2.1. Primary Objective (Endpoint) 
• to determine the prevalence of TPMT polymorphisms in healthy male 
subjects in Central South Africa 
• to determine the different alleles that are most prevalent in different 
racial groups in the healthy male subjects in Central South Africa 
• to compare the prevalence of mutant alleles in healthy male subjects in 
Central South Africa with data from the literature 
6.3. METHODOLOGY 
6.3.1. Study Plan 
This is a descriptive retrospective study that investigated the prevalence of TPMT 
polymorphism in healthy male subjects in Central South Africa. 
TPMT polymorphisms were determined in 540 healthy male subjects during 4 clinical 
trials performed between 23 February 2009 and 29 February 2012 at the PAREXEL 
Bloemfontein Early Phase Unit. The results were used during these clinical trials to 
exclude subjects that were either intermediate or poor TPMT metabolizers to prevent 
severe adverse events in certain trials. Only males were included in these studies and 
therefore the results of TPMT genotyping are only available for males. 
Genotyping tests were performed at the Chemical Pathology Department of the 
University of Cape Town, as well as Synexa Life Sciences in Cape Town. 
Genotyping tests at the University of Cape Town evaluated the following gene 
mutations: 
• TPMT*3C 
• TPMT*3B 
The evaluation of poor and intermediate metabolisers was performed as follows: 
• Point mutations at nucleotide 719 with a transition of purine A for purine G 
which constitutes to TPMT*3C allele -
• If the above tested positive, point mutations at nucleotide 460 with a transition 
of purine G for purine A were tested, which constitutes to TPMT*3B 
• If both tested positive, allele TPMT*3A was present and the subject was 
classified as a poor metabolizer 
• If only A719G tested positive and G460A tested normal, the subject was 
classified as an intermediate metabolizer 
Genotyping tests at Synexa Life Sciences, Cape Town evaluated the following gene 
mutations: 
• TPMT*2 
• TPMT*3B 
• TPMT*3C 
• TPMT*4 
• TPMT*3A 
Results were classified as homozygous wild type, heterozygous or homozygous 
mutant. 
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Study data were collected from 02 December 2013. The test results were listed in 
Excel format and used to evaluate the data relating to the study objectives. It was 
ensured that there were no duplicate tests and that subjects only had one test in the 
listings. 
6.3.2. Randomisation and Blinding (if applicable) 
Not Applicable 
6.4. STUDY POPULATION 
The criteria were set to ensure a homogeneous study population. To prevent bias, 
strict adherence to inclusion and exclusion criteria were maintained. 
6.4.1. Sampling/ Number of Subjects 
All valid genotyping TPMT tests that were performed were included in the analysis. 
6.4.2. Selection Criteria - Inclusion 
1 . Tests had to be a genotyping TPMT test 
2. If a repeat test was performed only the first valid test result was included. 
6.4.3. Selection Criteria - Exclusion 
1. Inconclusive test results were excluded. 
6.5. Study Procedures 
6.5.1. Informed Consent Process 
All subjects screened for studies at the PAREXEL Bloemfontein Early Phase Unit gave 
consent for the specific study and it was explained that TPMT data would be collected 
and analysed. Therefore, a waiver of informed consent for the current study was 
received from the Health Research Ethics Committee. 
6.6. Procedures and Data to be collected 
The following data were captured to perform the analysis. 
• Subject unique identification code 
• Subject race 
• Different TPMT alleles tested and the result of the test 
• Classification as normal, intermediate or poor metabolizer 
The selected data were entered into an Excel spread sheet which was then used for 
data analysis. 
6. 7. Intervention 
Not applicable. 
6.8. CHANGES TO THE STUDY CONDUCT 
No changes were made to the final protocol (dated 16 October 2013). 
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The following deviations occurred relating to the data collection and analysis. 
1. The first statistical analysis (done on 05 December 2013 by the Centre for 
Statistical Consultation, Stellenbosch University) did not include One Way 
Frequency analysis of all the different races and types of mutations. This was 
done by the PAREXEL Early Phase Bloemfontein Biostatistics and 
Programming Division, as the statistician mentioned in the protocol was not 
available over this period. The One Way Frequencies were performed on 02 
January 2014. The comparison data analysis for the literature and the study 
results was completed by 07 January 2014. 
2. The versions of SAS used for the analysis of data were 9.2 (PAREXEL 
Bloemfontein Early Phase Biostatistics and Programming division) and 9.3 
(Centre for Statistical Consultation, Stellenbosch University) and not 9.1.3 as 
stated in the protocol. This was due to updated software after the protocol was 
compiled. 
3. The data from the literature mentioned in the protocol were not USA data, but 
UK data. The study data were compared to this literature data. 
7. DATA ANALYSIS AND STATISTICAL METHODS 
7.1. Analysis Populations 
The results from all subjects who qualified based on the eligibility criteria were included 
in this study. 
7.2. Sample Size 
No formal sample size calculation was performed; all subjects for whom TPMT results 
were available for clinical trials performed between 23 February 2009 to 29 February 
2012 were used in the study. 
7.3. Analyses of Data 
The statistical evaluation of the study data were performed by the Center of Statistical 
Consultation at the University of Stellenbosch and the Division of Biostatistics and 
Programming, PAREXEL Early Phase Bloemfontein. Data were analyzed using SAS 
9.2 (PAREXEL) and 9.3 (University of Stellenbosch). 
The 95% confidence intervals for the binary proportions were used to estimate the 
study population prevalence. If small prevalence rates were observed, exact methods 
were used to calculate these confidence limits. 
In comparing the prevalence across different ethnic groups, a Chi-squared test was 
used. When small expected frequencies were observed a Fishers exact test for 2x2 
tables and an exact test for rxc tables were used to determine the association. 
To compare the prevalence rates to literature data, the assumption that the literature 
data are described as a constant was made; the analysis was a single sample T-test 
for proportions as well as a Chi-Squared test. Literature data used for the comparison 
of total prevalence were UK results and not USA results as stated in the study protocol. 
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A 5% significance level was assumed throughout. 
8. ADMINISTRATIVE OBLIGATIONS 
8.1. Source Data 
All applicable source data are stored at the PAREXEL Early Phase Unit, Bloemfontein 
for a period of at least 15 years or according to the applicable study protocol and 
contract. 
8.2. Data Collection and Management 
All results were entered into the Excel spread sheet by the researcher. A quality check 
was performed by a second person to ensure that all data were entered correctly. 
9.RESULTS 
9.1. Study Subject Disposition 
Altogether, results for 539 subjects were available for the subject disposition. The 
following racial groups were included in this study: Black (African), Caucasian and 
Mixed Race. 
Table 2: Study Subject Disposition 
Race Freauenc:;v - Percent 
Black 251 46.57 
Caucasian 261 48.42 
Mixed Race 27 5.01 
Total 539· 100.00 
*The actual total number is 539 due to 1 missing frequency in the data. One participant was not allocated a race. 
The number of Black and Caucasian subjects was similar. Mixed Race subjects only 
made up 5.01 % of the total study population. 
9.2. Prevalence of TPMT polymorphism 
The total prevalence of normal enzyme activity and TPMT polymorphism are presented 
in Table 3. 
Table 3: Prevalence of TPMT polymorphism 
. 
Result Tvoe Freauencv 
. 
Percent 
intermediate 33 6.11 
normal 484 89.63 
ooor 23 4.26 
Total 540 
. 
100.00 
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The prevalence of normal TPMT enzyme activity was 89.63%. TPMT polymorphism in 
the Central South African region was 10.37%. Of this total, 6.11 % were intermediate 
metabolizers and 4.26% were poor metabolizers. 
12.3 Prevalence of *2 allele abnormalities 
The prevalence of *2 allele abnormalities were as follows: 
Table 4: Prevalence of *2 allele abnormalities# 
.. Race 
Black Caucasian Mixed Race 
Value 
heterozygous Frequency 2 5 
Col Pct 
. 
0.89 2.43 
Total 
Percentaae 0.89 2.43 
#for *2 allele there were 84 missing frequencies, as not all studies tested for this allele. 
·cal Pct: Column Percent 
0 
0.00 
0.00 
Total 
7 
Of the total number of subjects, 2 Black subjects and 5 Caucasian subjects were 
heterozygous. This constitutes 0.89% and 2.43% respectively of the total study 
population. None of the Mixed Race subjects tested heterozygous for *2 allele. There 
were no clinical significant differences (p=0.5071) between the different races, although 
this could be largely due to the low sample size in these groups. 
12.4 Prevalence of *3A allele abnormalities 
The prevalence of *3A allele abnormalities were as follows: 
Table 5: Prevalence of *3A allele abnormalities# 
Race 
Black Caucasian Mixed Race Total 
Value 0 9 1 10 heterozygous Frequency 
Col Pct 0.00 4.81 4.76 
homozygous Frequency 0 2 2 4 
mutant Col Pct' 0.00 1.07 9.52 
Total Percentage 0.00 5.88 14.28 
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#for *3A allele there were 122 missing frequencies, as not all studies tested for this allele. 
·cal Pct: Column Percent 
Of the total number of subjects, 9 Caucasian and 1 Mixed Race subject were 
heterozygous. This constitutes 4.81% and 4.76% of the total study population per 
race. Two (2) Caucasian and 2 Mixed Race subjects were homozygous mutant for *3A 
allele. This reflects 1.07% and 9.52% of the total study population per racial group. 
None of the Black subjects tested heterozygous or homozygous mutant for *3A allele. 
There was a statistical significant difference between the different races (p=4.11 E-05), 
possibly due to no subjects with mutations for this allele. 
12.5 Prevalence of *38 allele abnormalities 
The prevalence of *3B allele abnormalities were as follows: 
Table 6: Prevalence of *3B allele abnormalities# 
Race 
Black Caucasian . Mixed 
. . Race 
Value 
heterozygous Frequency 13 16 5 
Col Pc( 5.65 7.51 20.00 
homozygous Frequency 2 0 0 
mutant Col pc( 0.87 0.00 0.00 
positive Frequency 0 6 0 
Col Pct 0.00 2.82 0.00 
Total 
Percentaoe 6.52 10.33 20.00 
#for "38 allele there were 72 missing frequencies, as not all studies tested for this allele. 
'col Pct: Column Percent 
Total 
34 
2 
6 
. 
Of the total number of subjects, 13 Black, 16 Caucasian and 5 Mixed Race subjects 
were heterozygous for *3B. This constitutes 5.61 %, 7.51 % and 20.00% of the total 
study population per race respectively. Two (2) Black subjects were homozygous 
mutant for *3B allele. This constitutes 0.87% of the study population per racial group. 
None of the Caucasian and Mixed Race subjects tested homozygous mutant for *3B 
allele. Six (6) Caucasian subjects tested positive for *3B, it was not confirmed by the 
applicable laboratory if these were heterozygous or homozygous mutant abnormalities. 
There is a statistical significant difference between the different races for this allele 
(p=0.0053), possibly due to the high prevalence in Mixed Race subjects. 
12.6 Prevalence of *3C allele abnormalities 
The prevalence of *3C allele abnormalities were as follows: 
Table 7: Prevalence of *3C allele abnormalities• 
Race Total 
Black Caucasian Mixed Race 
Value 
heterozygous Frequency 4 4 2 10 
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Col Pct 
. 
1.59 1.53 7.41 
homozygous Frequency 0 9 1 
mutant Col Pct . 0.00 3.45 3.70 
positive Frequency 5 6 0 
Col Pc( 1.99 2.30 0.00 
Total 
Percentaae 3.58 7.28 11.11 
11for *3C allele there was 1 missing frequency, as one subject were not allocated a race. 
·col Pct: Column Percent 
10 
11 
Of the total number of subjects, 4 Black, 4 Caucasian and 2 Mixed Race subjects were 
heterozygous for *3C. This constitutes 1.59%, 1.53% and 7.41% of the study 
population per race respectively. Nine (9) Caucasian and 1 Mixed Race subjects were 
homozygous mutant for *3C allele. This constitutes 3.45% and 3. 70% of the total study 
population per racial group respectively. None of the Black subjects tested 
homozygous mutant for *3C allele. Five (5) Black and 6 Caucasian subjects tested 
positive for *3C. It was not reported by the applicable laboratory if these were 
heterozygous or homozygous mutant abnormalities. None of the Mixed Race subjects 
tested positive for *3C. There was a statistical significant difference between the 
different races (p=0.0023). 
12.7 Prevalence of *4 allele 
None of the subjects tested positive or abnormal for *4 allele. All were homozygous 
wild type. 
Note: For * 4 allele, there were 83 missing frequencies as not all studies tested for this allele. 
10. DISCUSSION 
In 4 clinical trials performed at the Early Phase unit PAREXEL Bloemfontein, 540 
subjects were tested for TPMT polymorphism as part of the entry criteria for these 
trials. They all received a genotyping test for TPMT polymorphism and all subjects 
were included into this research study. 
Of the total study population, 89.63% tested normal (homozygous wild type) for TPMT 
enzyme activity. The rest had polymorphisms for the TPMT enzyme activity. Of this 
approximate 10%, 6.11 % were intermediate metabolizers and 4.26% were poor 
metabolizers. When this was compared to the literature, there was a difference for the 
intermediate and poor metabolizer prevalence. This difference was 4.26% for poor 
metabolizers compared to 0.3% according to the literature. There were 6.11 % 
intermediate metabolizers in this study, compared to approximate 10% according to the 
literature. 
This difference may be clinically important as poor metabolizers can present with 
severe adverse events, even life-threatening, when treated with thiopurine medications. 
When comparing the most prevalent allele polymorphism, differences to the literature 
were found. In Central South Africa exon *3B was most prevalent for Black (6.52%), 
Caucasian (10.33%) and Mixed Race (20.00) subjects. In the literature, exon *3C was 
most prevalent in Africans, Asians and South-Americans and exon *3A was most 
prevalent for Caucasians6•7•8•9•10 • No data were available for Mixed Race subjects that 
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can be compared to the South African population. One of the clinical trials included in 
this study only tested exon *38 if exon *3C tested abnormal. It was considered that 
*38 will not be abnormal if *3C is normal. However, from the data collected from the 
other 3 clinical trials used for this study, 19 subjects had an abnormal *38 exon with a 
normal *3C exon. Therefore it is a possibility that the percentages for exon *38 might 
be even higher than what is stated above, but still ii will be the most prevalent 
abnormality. This one clinical trial also did not test for *2, *3A and *4 routinely, 
therefore data may be incomplete. 
Table 8 compares different populations of different areas in the world and the most 
prevalent mutations. 
Table 8: Most prevalent allele mutations in different areas in the world per race (where 
available) 10 
;~~~~lj~~.~,~~ia·.· 
, 
South Africa Black *38 6.52 
Caucasian *38 10.33 
Mixed Raced *38 20.00 
Eurooe7 Caucasian *3A NA 
United States of Caucasian *3A 3.2 
America6 
African American *3C 2.4 
South East Asia NA *3C 5.0 
Araentina NA *3A 3.1 
Beloium NA *3A 8.0 
Brazil" White *3C NA I 4 individuals\ 
Non-white *2 NA I 4 individuals\ 
Mixed'" *3C 2.1 
China NA *3C 2.3 
Han *3C 2.2 - 2.6 
Jina *3C 1.9 
Yao *3C 3.7 
Uvnur *3C 3.1 
Colombia NA *3A 3.6 
Envpt NA *3C 1.3 
France Caucasian *3A 5.7-5.9 
Germanv NA *3A 8.0 
Ghana NA *3C 7.6 
ltalv NA *3A 3.9 
India NA *3C 0.8 
Jaoan NA *3C 0.8 - 2.2 
Jordari9 NA *3A 0.59 
Kenva NA *3C 5.4 
Malavsia NA *3C 2.3 
New Zeeland Caucasians *3A 5.0 
Poland NA *3A 2.7 
Norwav Saa mi *3C 3.3 
Sweden NA *3A 3.75 
Taiwan NA *3C 1.4-5.0 
NA=Not available 
South African data from this current study were included. 
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The article did not include TPMT*3B and it is not clear if it was not tested, or not 
detected in the mentioned studies. Therefore one should be cautious to conclude that 
it is only in South Africa that *3B is most prevalent. 
When evaluating the different polymorphisms in the current study, the following were 
seen. For exon *2 0.89% Black and 2.43% Caucasian subjects tested heterozygous. 
For exon *3A 4.81% Caucasians and 4.76% Mixed Race subjects tested heterozygous. 
Caucasians tested homozygous mutant in only 1.07% of the total study population, but 
9.52% Mixed Race subjects tested homozygous mutant. None of the Black subjects 
tested either heterozygous or homozygous mutant for exon *3A which is expected from 
the literature. 
For exon *3B, 5.65% Black, 7.51 % Caucasian and 20.00% Mixed Race subjects tested 
heterozygous. Homozygous mutant results were only seen in 0.87% Black subjects, 
but not at all in Caucasian and Mixed Race subjects. In Caucasian subjects 2.82% 
tested positive for *3B, but a breakdown of the different mutations were not done by the 
applicable laboratory, so it can be either heterozygous or homozygous mutant. 
With exon *3C, 1.59% Black, 1.53% Caucasian and 7.41% Mixed Race subjects tested 
heterozygous. No Black subjects tested homozygous mutant, but 3.45% Caucasians 
and 3. 7% Mixed Race subjects tested homozygous mutant. There were no Mixed 
Race subjects testing positive for exon *3C, but 1.99% Black and 2.3% Caucasian 
subjects tested positive. Again, no breakdown of the different mutations was done by 
the applicable laboratory for this exon. It can be expected that the Black and Mixed 
Race subjects have polymorphism for *3C, but a number of Caucasians also had 
polymorphism, which is different from the literature. A very low percentage of Black 
subjects were polymorphic for this allele, and none were homozygous mutant, which is 
unexpected if compared to the literature. 
None of the subjects tested polymorphic for exon *4. 
From these results, it may be possible that Black patients do not have to be tested for 
exon *3A when started on thiopurine medications. Also, no patient may need to be 
tested for exon *4, as none of the 540 subjects tested abnormal for this exon. However, 
if a polymorphism is expected and none of the other exons stated here are abnormal, 
this amongst others can be considered. 
It is interesting that about 20% of the Mixed Race study population had polymorphism 
for exon *3B, therefore it may be possible that a 5th of the Mixed Race population may 
be intermediate or poor metabolizers. However, the sample size was very small and 
this result should be viewed with caution. Research is required on a larger sample size 
to come to a more reliable conclusion. 
Of importance is that in Central South Africa, 4.26% of persons are poor metabolizers 
of thiopurine medications compared to the 0.3% poor metabolizers documented in 
literature. Although this difference was not statistically significantly (p=0.9689), it may 
be clinically meaningful. It might be necessary to test patients with adverse effects 
when using thiopurine medications to establish if they are poor or intermediate 
metabolizers. This can influence the specialist's decision to lower the dose, or to stop 
the medication. When considering the literature, it will only be necessary to stop the 
medication in a very small number of patients, however, in Central South Africa this 
number may be higher due to the higher prevalence of poor metabolizers. 
Currently TPMT enzyme activity is only tested in certain patient populations in South 
Africa due to cost constraints. As the prevalence of poor metabolizers were higher 
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than reported in the literature, it might be necessary to investigate the feasibility of 
testing for TPMT activity on a routine basis before starting treatment. Additional 
research is necessary in a broader population of the country and also to determine the 
health economic impact for these routine tests. The cost of treating severe adverse 
events such as bone marrow suppression may be more costly than to perform a routine 
TPMT activity test before starting with treatment. The specialist would be able to start 
at a lower dose if the enzyme activity is intermediate or can make use of another 
treatment option if the activity is poor. 
One should also consider which type of enzyme activity test should be performed. It is 
known that there is a high degree of concordance between TPMT genotype and 
phenotype in Caucasians. Africans are known to have around 20% less TPMT activity 
than Caucasians for the same allelic distribution8. Therefore it is clear that there are a 
number of considerations when treating the patient in the clinical setting. Genotyping 
was done for these clinical trials, but it might be more feasible and clinically relevant to 
perform a phenotype test in the clinical setting. This might also result in lower 
expenses and prevent any ethical issues associated with genotype testing. 
The shortcomings of this research study were that only 2 of the 4 clinical trials included 
in this study, had the full panel (*2, *3A, *3B, *3C and *4) of genotype tests. One study 
only tested for exon *3C, and if this was positive exon *3B was tested. The test also 
did not differentiate between the different abnormalities (heterozygous or homozygous 
mutant). Therefore 84 subjects only had limited results. Another 38 subjects from a 
second study did not have *3A results. There were missing frequencies due to this for 
all the analysis and the influence is difficult to determine. 
Another factor that should caution the generalisation of the results is the low number of 
Mixed Race subjects in these 4 clinical trials. Only 5.01 % of the total study population 
was Mixed Race, and therefore the results should be viewed with caution and need to 
be confirmed in a larger sample size. 
11. CONCLUSION 
Although it was expected that the number of poor and intermediate metabolizers would 
be similar to data that are available in the literature, it was confirmed that the 
percentage of poor metabolizers is more than what is documented in the literature. 
The percentage of normal metabolizers and total polymorphisms are similar to what is 
seen in the literature. 
The most prevalent polymorphism was in exon *3B for all the racial groups. This differs 
from what is available in the literature for the rest of the world, where exon *3A is most 
prevalent in Caucasian and *3C is most prevalent in Africans, Asians and South 
Americans. No data was available for Mixed Race persons that could be compared in 
this study. 
Twenty (20) percent of Mixed Race subjects tested heterozygous for exon *3B, which 
is significantly more than any other race and for any other abnormality, but as the 
sample size for Mixed Race subjects was very small these results should be viewed 
with caution. 
Exon *4 is most likely not present in South Africans and could be omitted from standard 
tests. However, if a polymorphism is expected and none of the other exons stated here 
are abnormal, this amongst others can be considered. 
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